Editorial

Editorial

• Güven Aslan

Review

The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer

• Bertrand Tombal

Is prostate cancer be screened according to Turkey data?

• Rahmi Gökhan Ekin
• Ferruh Zorlu

Active surveillance in low risk prostate cancer

• Ozan Bozkurt
• Ömer Demir

Treatment options in low-intermediate risk prostate cancer

• Saadettin Yılmaz Eskiçorapçı
• Deniz Bolat

Radiotherapy in low and intermediate-risk prostate cancer

• Deniz Yalman

Robot-assisted radical prostatectomy: Operative technique — step by step

• Bora Özveren
• Levent Türkeri

Surgical treatment and/or radiotherapy in high risk prostate cancer

• Fatih Bıçaklıoğlu
• Cenk Acar
• Sinan Sözen

Androgene suppression therapy in addition to radical radiotherapy in high risk prostate carcinoma

• İlknur Bilkay Görken

New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor

• Yavuz Selim Süral
• Çağ Çal

New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate

• Bülent Akdoğan

New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T

• Gürbüz Görümlü
• Erdem Göker

New treatment options in castration resistant prostate cancer: denosumab, alpharadin

• Hakan Gemalmaz

Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer

• İlker Çelen
• Yasin Ceylan

How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?

• İlker Çelen
• Murat Lekili

Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer

• Hayrettin Şahin
• Hasan Deliktaş

Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy

• Ali Cansu Bozacı
• Sertaç Yazıcı